Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
Dirk Schadendorf(Essen University Hospital), Georgina V. Long(The University of Sydney), Jacob Schachter, Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Marta Nyakas(Oslo University Hospital), Thierry Lesimple, Kohinoor Dasgupta(Heidelberg University), Axel Hauschild(University Hospital Schleswig-Holstein), Ruth Plummer(National Health Service), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Richard Kefford(Broad Institute), James Larkin(Royal Marsden NHS Foundation Trust), Laurent Mortier, Victoria Atkinson(The University of Queensland), Roy Koruth(Novartis (United States)), Bijoyesh Mookerjee(Novartis (United States)), Mario Santinami(Fondazione IRCCS Istituto Nazionale dei Tumori), Reinhard Dummer(University Hospital of Zurich), Stephanie Manson(Novartis (United States)), Andrew Haydon(The Alfred Hospital), John M. Kirkwood(UPMC Hillman Cancer Center), Caroline Robert(Université Paris-Sud), Mario Mandalà(University of Perugia)
Cited by 56
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k